| Novo Nordisk Health Care AG Patent applications |
| Patent application number | Title | Published |
|---|
| 20120108512 | STABLE PHARMACEUTICAL COMPOSITIONS OF PEPTIDE DERIVATIZED USING AN OXIME LINKER - The invention relates to stable pharmaceutical compositions comprising a therapeutic peptide derivatized with a property-modifying group, wherein the property-modifying group is conjugated to the peptide by use of a linker comprising an oxime bond. | 05-03-2012 |
| 20110306548 | STABLE GROWTH HORMONE COMPOUNDS - The present invention relates to stable growth hormone (GH) compounds, which through the introduction of cysteine residues have disulphide bridges, which make the compounds resistant to proteolytic degradation. | 12-15-2011 |
| 20110287518 | Polypeptide Purification - The invention relates to the purification of different gamma carboxylated forms of a polypeptide using ion exchange chromatography. In particular, the invention provides a method for purifying a polypeptide having a desired content of gamma-carboxyglutamic acid from a sample comprising mixture of species of said polypeptide having different contents of gamma-carboxyglutamic acid, said method comprising the steps of: (a) loading said sample onto an anion exchange chromatography material; (b) eluting said polypeptide using a solution at a pH of less than pH 9.0 comprising at least one salt selected from ammonium acetate, ammonium chloride and sodium acetate; and (c) selecting a fraction obtained from said elution wherein the polypeptides in the fraction have the desired content of gamma-carboxyglutamic acids. | 11-24-2011 |
| 20110265557 | Method of Quality Control Testing a Factor XIII Containing Sample - The invention relates to a method of quality control testing a Factor XIII (FXIII) containing sample which comprises the step of detecting the presence of and/or measuring the concentration of pre-activated FXIII (FXIIIao) in said sample and to a quality control kit for determining the quality of a Factor XIII (FXIII) containing sample. Preferably, an anion-exchange chromatographic column is used, as well as the fluorescent substrate Abz-NE (Cad-Dnp) EQVS PLTLLK-OH. | 11-03-2011 |
| 20110229453 | BLOOD COAGULATION FACTOR INHIBITORS - The invention relates to novel compounds with formula (I) useful as blood coagulation factor inhibitors. The compounds (I) may be used for treatment of thrombotic conditions or as stabilizers of liquid formulations of blood coagulation factors, in particular liquid formulations of FVIIa, Factor VII variants, or Factor VII derivatives. | 09-22-2011 |
| 20110223151 | CONJUGATED PROTEINS WITH PROLONGED IN VIVO EFFICACY - The invention relates to conjugated proteins, in particular but not exclusively, blood coagulation factors, to processes for preparing said conjugates, to pharmaceutical compositions comprising said conjugates and to the use of the conjugates in therapy, in particular but not exclusively, for the treatment of diseases alleviated by blood coagulation factors such as the prophylactic treatment of hemophilia. | 09-15-2011 |
| 20110144017 | Protein conjugates and methods for their preparation - Reductive amination of peptide-derived aldehydes with anilines or heteroarylamines containing a property-modifying group provides new, hydrolytically stable protein conjugates, suitable for therapy. | 06-16-2011 |
| 20110118183 | N-GLYCOSYLATED HUMAN GROWTH HORMONE WITH PROLONGED CIRCULATORY HALF-LIFE - The present invention relates to novel human growth hormone (hGH) variant(s) with one or more N-glycans. The hGH variants of the invention comprises an amino acid sequence which includes at least one N-glycosylation motif (N-X-S/T) arising from one or more mutations not present in the wild type hGH. The hGH variants of the invention have a prolonged circulatory half-life and thus can be effectively used as a protein therapeutic for disease states that will benefit from increased levels of hGH. The process of obtaining the hGH variants is also encompassed by the invention. | 05-19-2011 |
| 20110112029 | LOW VISCOSITY COMPOSITIONS COMPRISING A PEGYLATED GLA-DOMAIN CONTAINING PROTEIN - The present invention relates to a method for lowering the viscosity of compositions comprising Vitamin K-dependent proteins. | 05-12-2011 |
| 20110104142 | FORMULATIONS OF PEG-FUNCTIONALISED SERINE PROTEASES WITH HIGH CONCENTRATIONS OF AN AROMATIC PRESERVATIVE - The invention relates to a liquid, aqueous pharmaceutical composition comprising a Factor VII polypeptide (i) functionalised with one or more polyethylene glycol (PEG) moieties, said PEG moieties having a molecular weight of at least 300 Da; a buffering agent (ii) suitable for keeping pH in the range of from about 5.0 to about 9.0; and at least one aromatic preservative (iii) in a concentration of at least 0.1 mg/mL. | 05-05-2011 |
| 20110070610 | Processing Enzymes Fused to Basic Protein Tags - The invention is related to processing enzyme comprising an N-terminally attached tag derived from highly basic proteins from thermophilic bacteria. The processing enzymes are useful for modifying proteins. They can be produced in high yields and can be effectively separated from the modified protein after use. | 03-24-2011 |
| 20110003752 | New Blood Coagulation Factor Inhibitors - The invention relates to novel compounds with formula (I) X | 01-06-2011 |
| 20110003363 | Reduction of Dimer Content in Factor VII Polypeptide Compositions by Heat Treatment - The present application relates to a method of reducing the content of dimers in Factor VII polypeptide composition by heat treatment. | 01-06-2011 |
| 20100303786 | Stabilisation of Liquid-Formulated Factor VII(A) Polypeptides by Aldehyde-Containing Compounds - The present invention is directed to liquid, aqueous pharmaceutical compositions stabilised against chemical and/or physical degradation containing Factor VII polypeptides, and methods for preparing and using such compositions, as well as vials containing such compositions, and the use of such compositions in the treatment of a Factor VII-responsive syndrome. The main embodiment is represented by a liquid, aqueous pharmaceutical composition comprising at least 0.01 mg/mL of a Factor VII polypeptide (i); a buffering agent (ii) suitable for keeping pH in the range of from about 4.0 to about 9.0; and at least one stabilising agent (iii) comprising a R—CHO motif, e.g. Benzaldehyde, 3-hydroxybenzaldehyde, 4-hydroxybenzaldehyde, or 5-formyl-4-methylimidazole. | 12-02-2010 |
| 20100294677 | High Concentration Factor VII Polypeptide Formulations Comprising an Aromatic Preservative and an Antioxidant - The present invention relates to pharmaceutical compositions comprising at least 10 mg/mL of a Factor VII polypeptide (i); a buffering agent (ii) suitable for keeping pH in the range of from about 5.0 to about 9.0; at least one aromatic preservative (iii) in a concentration of at least 0.1 mg/mL; and at least one antioxidant (iv) in a concentration of at least 0.1 mg/mL; the composition optionally comprising further components, with the proviso that none of such further components are Factor VII polypeptide stabilizing agents selected from (a) metal-containing agents, wherein said metal is selected from the group consisting of first transition series metals of oxidation state +II, except zinc; and (b) stabilising agent comprising a —C(═N—Z1-R1)-NH—Z2-R2 motif. | 11-25-2010 |
| 20100204452 | Purification of Factor VIII Using a Mixed-Mode or Multimodal Resin - A method for purifying a recombinant protein using a multimodal or mixed mode resin containing ligands which comprise a hydrophobic part and a negatively charged part is described. The invention is advantageous in that it is a single step chromatographic process which does not require adjustment of pH or conductivity during loading step and results in high yield and potency. The process is used for the purification of recombinant compositions of coagulation factor, particularly recombinant Factor VIII. | 08-12-2010 |
| 20100197573 | Transglutaminase Mediated Conjugation of Growth Hormone - A method for PEGylating growth hormone, said method comprising reacting growth hormone with an amine comprising nucleophile which further comprises a first functional group in the presence og TGase to form a transaminated growth hormone, followed by a reaction of said transaminated growth hormone with a PEG which has been functionalised with a second functional group, wherein said first and second functional groups are selected so that they react to form a covalent bond. | 08-05-2010 |
| 20100166730 | Liquid, Aqueous Pharmaceutical Composition of Factor VII Polypeptides - The present invention is directed to liquid, aqueous pharmaceutical compositions containing Factor VII polypeptides, and methods for preparing and using such compositions, as well as vials containing such compositions, and the use of such compositions in the treatment of a Factor VII-responsive syndrome, e.g., bleeding disorders, including those caused by clotting Factor deficiencies (e.g. haemophilia A, haemophilia B, coagulation Factor VII deficiency); by thrombocytopenia or von Willebrand's disease, or by clotting Factor inhibitors, and intra cerebral haemorrhage, or excessive bleeding from any cause. The preparations may also be administered to patients in association with surgery or other trauma or to patients receiving anticoagulant therapy. More particularly, the invention relates to liquid compositions stabilised against chemical and/or physical degradation. The main embodiment is represented by a liquid, aqueous pharmaceutical composition comprising a Factor VII polypeptide (i); a buffering agent (ii) suitable for keeping pH in the range of from about 4.0 to about 9.0; at least one metal-containing agent (iii), wherein said metal is selected from the group consisting of first transition series metals of oxidation state +II, except zinc, such as chromium, manganese, iron, cobalt, nickel, and copper; and a non-ionic surfactant (iv). | 07-01-2010 |
| 20100137570 | HOST CELL PROTEIN KNOCK-OUT CELLS FOR PRODUCTION OF THERAPEUTIC PROTEINS - The present invention relates to methods and means for making Vitamin K-dependent protein compositions which are devoid or substantially devoid of protein contaminants. In particular, methods and means useful for the reduction or elimination of protein contaminants also being Vitamin K-dependent proteins are described. | 06-03-2010 |
| 20100105617 | C-Terminal Attachment of Two Chemical Groups to Peptides - The present invention relates to a method for C-terminal attachment of two property-modifying groups to a peptide. | 04-29-2010 |
| 20100056428 | MODIFIED PROTEINS - Method of conjugating glycoproteins by means of chemical modification is provided as well as new modified glycoproteins. | 03-04-2010 |
| 20100009917 | Modulating Enzymatic Processes by Addition of Diolcontaining Substances - The present invention relates to a method for increasing the selectivity of an enzyme, which method comprises performing the reaction in the presence of an enhancing compound selected from one of ethylene glycol, propylene glycol or glycerol. | 01-14-2010 |
| 20100009407 | Processing Enzymes Fused to Basic Protein Tags - The invention is related to processing enzyme comprising an N-terminally attached tag derived from highly basic proteins from thermophilic bacteria. The processing enzymes are useful for modifying proteins. They can be produced in high yields and can be effectively separated from the modified protein after use. | 01-14-2010 |
| 20090325865 | Liquid Formulations of Pegylated Growth Hormone - Pharmaceutical compositions comprising pegylated growth hormone at pH 7 or below are provided. | 12-31-2009 |
| 20090318349 | TRANSGLUTAMINASE VARIANTS WITH IMPROVED SPECIFICITY - Variants of transglutaminase from | 12-24-2009 |
| 20090252720 | Prolonged FIX Analogues and Derivatives - The invention is related to FIX analogues which have an increased circulation time in the blood stream before activation compared to that that of native FIX (and a week after injection to a patient retains at least about 5% of the FIX activity compared to the initial activity peak value reached after injection). The claimed FIX analogues comprise an inserted cysteine residue which has been further modified by conjugation with a chemical group increasing the molecular weight of the FIX analogue. | 10-08-2009 |
| 20090130086 | FXIII Variants with Improved Properties - The present invention concerns variant factor XIII, wherein the rate of activation of said variant by thrombin is faster than for wild type FXIII. Methods for enhancing fibrin clot formation, pharmaceutical compositions and the use for the manufacture of medicaments wherein the variant factor XIII is applied are disclosed. | 05-21-2009 |
| 20090117640 | Transglutaminase Variants with Improved Specificity - Variants of transglutaminase from | 05-07-2009 |
| 20090111751 | Method of Removing a Non-Metallic Protein Inhibitor From a Liquid Pharmaceutical Preparation - The invention relates to a method for removing a protein inhibitor from a liquid pharmaceutical preparation, said method comprising the steps of: (a) providing a sealed container comprising an initial liquid pharmaceutical preparation comprising (i) a protein belonging to the group of serine proteases/Vitamin K-dependent proteins and (ii) a non-metallic inhibitor for said protein; (b) contacting said pharmaceutical preparation with a solid phase polymeric material capable of retaining at least a substantial portion of said inhibitor; and (c) separating said liquid pharmaceutical preparation from said solid phase polymeric material so as to obtain a resulting liquid pharmaceutical preparation having a reduced concentration of said inhibitor compared to the initial liquid pharmaceutical preparation. | 04-30-2009 |
| 20090100533 | Expression of gamma-carboxylated polypeptides in gamma-carboxylation deficient host sytems - The present invention relates to a novel method for preparing gamma-carboxylated poly-peptides, including coagulation Factors VII, IX, X and Protein C. The present invention also relates to novel host cells and recombinant vectors to be used in this improved method for preparing gamma-carboxylated polypeptides. | 04-16-2009 |
| 20090041747 | Compounds for Stabilizing Factor VII Polypeptide Formulations - The invention relates to novel compounds with formula (I) and their use in stabilization of Factor VIIa or other Factor VII polypeptides, particularly in aqueous liquid compositions thereof. | 02-12-2009 |
| 20080299611 | Host Cell Protein Knock-Out Cells for Production of Therapeutic Proteins - The present invention relates to methods and means for making Vitamin K-dependent protein compositions which are devoid or substantially devoid of protein contaminants. In particular, methods and means useful for the reduction or elimination of protein contaminants also being Vitamin K-dependent proteins are described. | 12-04-2008 |
| 20080254514 | Production of a Polypeptide in a Serum-Free Cell Culture Liquid Containing Plant Protein Hydrolysate - The invention concerns a method for large-scale production of a polypeptide in eukaryote cells contained in a serum-free culture liquid, said method comprising (i) a propagation phase for said cells, where the cells are propagated in a first cell culture liquid, and (ii) a production phase for said cells, where the cells are present in a second cell culture medium liquid, wherein each of the cell culture liquids comprise a plant protein hydrolysate, and wherein the ratio between the concentration of the plant protein hydrolysate (C | 10-16-2008 |
| 20080227691 | Blood Coagulation FVIII Analogues - The invention is related to a FVIII analogue which has a circulation time in the blood stream before activation of at least about two times of that of native FVIII and a week after injection to a patient retains at least about 5% of the FVIII activity compared to the initial activity peak value reached after injection. The claimed FVIII analogues comprise a targeted disruption of one or more of the clearance sites in the FVIII molecule by introduction of at least one N-glycosylation site or by introduction of at least one Cys residue within or spatially close to the clearance site in the A2 domain or a combination thereof. The inserted cysteine residues may be further modified by conjugation with a chemical group increasing the molecular weight of the FVIII analogue. | 09-18-2008 |
| 20080206225 | Closed Container Comprising an Activated Factor VII Polypeptide, Processes for the Preparation of the Same, and a Kit and a Method for Use of the Kit - The present invention relates to a closed container holding a composition of an activated Factor VII polypeptide in an amount of in the range of 2.5-90 mg per imL volume of the container. The invention also relates to various processes for the preparation of such closed containers, a kit including such containers and a method of using the kit. | 08-28-2008 |
